A Study to Observe the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment

Prospective Non-Interventional Study Evaluating the Long-term Safety of Odevixibat in Patients With Alagille Syndrome (ALGS)

This study will collect information from patients with ALGS who are using odevixibat in their daily lives. Odevixibat is a medication that helps patients with ALGS, a rare disease that affects the liver and causes itching.

The main aim of this study is to observe the long-term, everyday safety of the drug odevixibat in patients with ALGS who are receiving ongoing treatment.

Inclusion Criteria:

• Diagnosed with ALGS.
• On (or starting) active odevixibat treatment.
• Aged 6 months or older at the time of consent.

Exclusion Criteria:

• Currently participating in a clinical trial with odevixibat.
• Currently participating in any interventional clinical trial for ALGS.
• Have any contraindication to odevixibat as per the locally approved label.